FLHLF News and Press, Filament Health

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Nov. 7, 2025 /CNW/ - Filament Health Corp.  (OTC: FLHLF) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug de...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Aug. 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament " or the " Company "), a clinical‐stage nat...

FILAMENT HEALTH ANNOUNCES FIRST-EVER COMPASSIONATE USE APPROVAL FOR PSILOCYBIN IN THE EUROPEAN UNION Canada NewsWire Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression VANCOUVER, BC , Jul...

FILAMENT HEALTH ANNOUNCES TWO PHASE 2 RESEARCH TRIALS IN PARTNERSHIP WITH UNIVERSITY COLLEGE LONDON Canada NewsWire UCL will study PEX010, the company's botanical psilocybin drug candidate, in trials investigating human perception, cognition, and therapeutic optimization ...

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that an access and benefit sharing agreement focu...

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PSILOCYBIN FOR ALCOHOL USE DISORDER AND POST-TRAUMATIC STRESS DISORDER IN VETERANS AND FIRST RESPONDERS Canada NewsWire The clinical trial at the University of Washington will study Filament's b...

FILAMENT HEALTH ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF ALABAMA AT BIRMINGHAM FOR DATA FROM A CLINICAL TRIAL OF PSILOCYBIN FOR THE TREATMENT OF COCAINE USE DISORDER Canada NewsWire The data supports Filament's PEX010 drug development program targeting stimul...

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER Canada NewsWire The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC ...

FILAMENT HEALTH ANNOUNCES TRANSITION FROM OTCQB TO OTC PINK LIMITED Canada NewsWire VANCOUVER, BC , May 27, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug developme...

FILAMENT HEALTH ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA Canada NewsWire VANCOUVER, BC , May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psyc...